1. Thailand Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Mega Lifesciences Public Company Limited

Mega Lifesciences Public Company Limited

MEGA-R.BK
Mega Lifesciences Public Company LimitedTH flagStock Exchange of Thailand
38.00
THB
+0.25
- -
33.13BMarket Cap
Mega Lifesciences Public Company Limited
MEGA-R.BK
(Stock Exchange of Thailand)

Recent

price

38.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
6.65
8.19
9.42
8.93
9.18
10.18
11.09
11.77
12.78
14.44
16.21
17.99
17.99
17.6
16.23
16.48
Revenue per Share
- -
0.62
0.79
0.84
0.63
0.8
0.92
1.29
1.39
1.31
1.6
2.23
2.57
2.29
2.31
2.19
2.37
Basic EPS, GAAP
- -
0.26
-0.39
0.09
0.46
0.48
1.11
0.81
0.18
1.1
1.58
2.94
1.93
1.87
2.46
2.41
2.95
Free Cash Flow per Basic Share
- -
0.13
0.2
1.13
0.28
0.41
0.47
0.54
0.71
0.71
0.77
1.06
1.61
1.65
1.6
1.6
1.6
Dividend per Share
- -
1.89
2.49
2.2
2.24
2.63
3.07
3.82
4.51
5.06
5.86
7.03
8.05
8.68
9.4
10
10.66
Book Value per Share
- -
1.8
2.08
4.66
4.33
4.74
4.4
5.03
5.3
5.82
6.5
7.65
8.54
9.16
9.82
10.23
10.55
Tangible Book Value per Share
- -
730
728
747
865
865
865
865
865
871
872
872
872
872
872
872
871
Basic Weighted Avg Shares
- -
4,857
5,965
7,034
7,730
7,945
8,810
9,597
10,182
11,130
12,589
14,136
15,686
15,681
15,344
14,147
14,348
Sales/Revenue/Turnover
- -
11.39
10.95
10.29
8.2
8.67
11.49
14.13
13.14
12.6
13.4
15.15
17.09
18.52
21.96
20.52
21.1
Operating Margin (%)
- -
69
76
99
131
145
152
152
148
160
256
274
272
286
283
283
279
Depreciation Expense
- -
456
578
624
548
696
795
1,113
1,206
1,139
1,393
1,947
2,242
1,993
2,012
1,912
2,067
Net Income, GAAP
- -
18.99
17.05
17.61
14.15
15.97
14.77
14.31
14.39
12.32
14.44
14.76
13.67
11.9
14.44
20.47
22.04
Effective Tax Rate (%)
- -
9.39
9.69
8.87
7.09
8.76
9.02
11.59
11.84
10.23
11.06
13.77
14.29
12.71
13.12
13.51
14.4
Profit Margin (%)
543
933
1,079
2,678
2,329
3,068
2,536
3,104
2,683
3,072
3,358
4,448
5,052
5,563
6,312
6,256
6,555
Working Capital
26
5
347
212
137
84
7
- -
2
1
111
132
109
132
140
146
121
LT Debt
850
1,318
1,710
3,693
3,978
4,335
4,680
5,244
5,724
6,175
6,979
8,025
8,777
9,302
9,877
10,215
10,507
Total Equity
- -
25.02
21.2
15.39
11.62
11.86
16.29
20.4
17.97
17.52
19.16
22.16
25.54
26.59
28.26
20.99
20.91
Return on Invested Capital (%)
- -
25.67
23.04
23.12
21.85
25.69
25.76
31.76
28.47
23.55
26.34
32.17
32.53
26.48
24.78
21.63
22.18
Return on Capital (%)
- -
39.1
36.23
36.11
30.56
33.03
32.24
37.31
33.48
27.43
29.27
34.64
34.1
27.32
25.53
22.62
23.06
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
495
537
543
LT Borrowings
- -
- -
- -
LT Finance Leases
122
146
121
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
872
872
872
Market Capitalization
26,875
29,042
29,601

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
10,443
11,353
11,642
Cash, Cash Equivalents & STI
3,773
4,629
4,637
Accounts Receivable, Net
3,108
3,306
3,300
Inventories
3,103
3,038
3,259
Total Current Liabilities
4,540
5,096
5,088
Payables & Accruals
3,919
4,337
4,414
ST Debt
495
537
543
Deferred Revenue
- -
91
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9%
7.99%
3.43%
Free Cash Flow
65.42%
15.75%
-1.9%
Net Income, GAAP
11.92%
7.97%
-4.99%
Sales/Revenue/Turnover
6.16%
2.65%
-7.8%
Total Cash Common Dividend
15.98%
17.87%
0.03%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,733
3,954
4,001
3,657
15,344
2025
3,208
3,399
3,876
3,664
14,147
2026
3,408
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.55
0.59
0.44
- -
2.31
2025
0.52
0.45
0.57
- -
2.19
2026
0.69
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.8
0.8
- -
1.6
2025
- -
0.8
0.8
- -
1.6
2026
- -
- -
- -
- -
- -
Similar Companies
CBD Life Sciences Inc. (CBDL)
Viatris Inc. (VTRS)
Legacy Technology Holdings, Inc. (LTHO)
Heritage Cannabis Holdings Corp. (CANN.CN)
Zhejiang Garden Biopharmaceutical Co.,Ltd. (300401.SZ)
TTY Biopharm Company Limited (4105.TWO)
Business
Mega Lifesciences Public Company Limited manufactures, markets, sells, and distributes pharmaceutical products, nutraceutical supplements, over-the-counter medications, herbal remedies, vitamins, probiotics, and fast-moving consumer goods in the health and wellness industry; its core offerings span medical nutrition, sports nutrition, general wellbeing, hair care, children's care, digestive health, bone and joint support, skin care, women's and men's health, as well as prescription medicines targeting allergies, blood circulation, diabetes, dermatology, gastroenterology, ophthalmology, pain management, respiratory conditions, and urology. The company operates through three main segments including Brands via MEGA We Care, Distribution via MAXXCARE, and Original Equipment Manufacturing with facilities in Thailand and Australia accredited by international good manufacturing practice authorities; it serves markets across Asia-Pacific, Middle East, Africa, CIS countries, Latin America, and Europe, with a strong presence in Southeast Asia and Sub-Saharan Africa. Founded in 1982 and headquartered in Bangkok, Thailand, Mega Lifesciences functions as a subsidiary of Unistretch Limited and employs approximately 900 people. In recent developments, the company sustains controlled selling, general, and administrative expenses amid revenue challenges from its Maxxcare operations in Myanmar, while allocating capital expenditures of around THB 483 million toward manufacturing expansions in Indonesia, Thailand, and Australia, including new dosage forms and plant upgrades; it advances strategic initiatives to deepen therapeutic categories such as dermatology, diabetes, respiratory, gut health, and pain relief, alongside pipeline development for branded consumer health and pharmaceutical growth aiming to double its market size over five years, and pursues licensing applications and construction for a new site in Myanmar by mid-2026.